Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2929 in Generalized Pustular Psoriasis
NCT06433531Phase 1Active, not recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQH2929 in generalized pustular psoriasis (GPP), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Adverse events (AE), Serious adverse events (SAE) and 2 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
TQH2929
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT06433531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433531.